These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3034705)

  • 1. Present knowledge of poliovirus and perspectives for future vaccines.
    Crainic R; Blondel B
    Dev Biol Stand; 1987; 66():377-83. PubMed ID: 3034705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antigenicity determination of inactivated poliovirus--the micro-neutralization inhibition test].
    Jiang SD; Pye D
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1985 Aug; 7(4):309-12. PubMed ID: 3011295
    [No Abstract]   [Full Text] [Related]  

  • 3. Approaches to the construction of new candidate poliovirus type 3 vaccine strains.
    Almond JW; Stone D; Burke K; Skinner MA; Macadam AJ; Wood D; Ferguson M; Minor PD
    Dev Biol Stand; 1993; 78():161-9; discussion 169-70. PubMed ID: 8388827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neutralizing antibodies in the sera of persons vaccinated with intradermal poliovirus vaccine].
    Jarzabek Z; Kańtoch M
    Przegl Epidemiol; 1984; 38(3):323-6. PubMed ID: 6098935
    [No Abstract]   [Full Text] [Related]  

  • 5. Virology. 'Biased' viruses suggest new vaccine strategy for polio and other diseases.
    Enserink M
    Science; 2008 Jun; 320(5884):1709. PubMed ID: 18583587
    [No Abstract]   [Full Text] [Related]  

  • 6. [The use of immunomodulators to enhance postvaccinal immunity to experimental poliomyelitis].
    Bondarenko VI; Zadorozhnaia VI; Buraia TA; Gritsenko LN
    Mikrobiol Z; 1995; 57(6):41-5. PubMed ID: 8714398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One hundred years of poliovirus pathogenesis.
    Racaniello VR
    Virology; 2006 Jan; 344(1):9-16. PubMed ID: 16364730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
    Yang C; Shi H; Zhou J; Liang Y; Xu H
    Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering attenuated virus vaccines by controlling replication fidelity.
    Vignuzzi M; Wendt E; Andino R
    Nat Med; 2008 Feb; 14(2):154-61. PubMed ID: 18246077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent trends in veterinary vaccines.
    Bittle JL
    Prog Clin Biol Res; 1985; 178():621-6. PubMed ID: 4011619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A deader vaccine?
    Minor P
    Nat Med; 2008 Feb; 14(2):120-1. PubMed ID: 18256612
    [No Abstract]   [Full Text] [Related]  

  • 12. Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication.
    Minor P
    Vaccine; 2009 May; 27(20):2649-52. PubMed ID: 19428874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular evolution of oral poliovirus vaccine strains during multiplication in humans and possible implications for global eradication of poliovirus.
    Friedrich F
    Acta Virol; 2000 Apr; 44(2):109-17. PubMed ID: 10989702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
    Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
    J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current concepts of the antigenic structure and attenuation mechanisms of the poliomyelitis virus].
    Gendon IuZ
    Vopr Virusol; 1988; 33(4):389-92. PubMed ID: 2461613
    [No Abstract]   [Full Text] [Related]  

  • 16. Prospective inactivated or live poliovirus vaccine: effectiveness in the 21st Century.
    Arya SC; Agarwal N
    Expert Rev Vaccines; 2009 Feb; 8(2):127-30. PubMed ID: 19196189
    [No Abstract]   [Full Text] [Related]  

  • 17. The pathogenesis of poliomyelitis: what we don't know.
    Nathanson N
    Adv Virus Res; 2008; 71():1-50. PubMed ID: 18585526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poliomyelitis prevention: enhanced-potency inactivated poliomyelitis vaccine--supplementary statement.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1987 Dec; 36(48):795-8. PubMed ID: 3119980
    [No Abstract]   [Full Text] [Related]  

  • 19. [Genetic evolution of poliovirus: success and difficulties in the eradication of paralytic poliomyelitis].
    Blondel B; Autret A; Brisac C; Pelletier I; Martin-Latil S; Jegouic S; Bessaud M; Joffret ML; Balanant J; Colbère-Garapin F; Delpeyroux F
    Med Trop (Mars); 2008 Apr; 68(2):189-202. PubMed ID: 18630055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence on the safety and efficacy of live poliomyelitis vaccines currently in use, with special reference to type 3 poliovirus.
    Bull World Health Organ; 1969; 40(6):925-45. PubMed ID: 4310724
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.